News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|September 18, 2024

Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib

Author(s)Ryan Haumschild, PharmD, MS, MBA, Marwan Fakih, MD , Michael Morse, MD, MHS, FACP

Medical experts compare the efficacy and safety of new therapies, including FTD/TPI plus bevacizumab and fruquintinib, to regorafenib for metastatic colorectal cancer.

Episodes in this series

EP. 1 Navigating Beyond FOLFOX/FOLFIRI: Key Therapies in Advanced mCRC

EP. 1 Navigating Beyond FOLFOX/FOLFIRI: Key Therapies in Advanced mCRC

EP. 2 Real-World Impact of SUNLIGHT Outcomes in mCRC

EP. 2 Real-World Impact of SUNLIGHT Outcomes in mCRC

EP. 3 Fruquintinib in mCRC: Key Insights From FRESCO-2

EP. 3 Fruquintinib in mCRC: Key Insights From FRESCO-2

EP. 4 Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib

EP. 4 Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib

EP. 5 Optimizing mCRC Therapy Sequencing: Key Considerations and Future Directions

EP. 5 Optimizing mCRC Therapy Sequencing: Key Considerations and Future Directions

EP. 6 Guiding Patients Through Third-Line mCRC Therapy Decisions

EP. 6 Guiding Patients Through Third-Line mCRC Therapy Decisions

EP. 7 Navigating Toxicity: Comparing Third-Line mCRC Therapies

EP. 7 Navigating Toxicity: Comparing Third-Line mCRC Therapies

EP. 8 Evaluating Quality of Life and Adherence With mCRC Treatment Options

EP. 8 Evaluating Quality of Life and Adherence With mCRC Treatment Options

EP. 9 Integrating Support Services and Caregiver Roles in mCRC Care

EP. 9 Integrating Support Services and Caregiver Roles in mCRC Care

EP. 10 mCRC Treatment Access: IRA Cost Cap Impact and Final Insights

EP. 10 mCRC Treatment Access: IRA Cost Cap Impact and Final Insights

Video content above is prompted by the following:

How do these new therapy options (FTD/TPI plus bevacizumab, fruquintinib) compare with regorafenib in terms of efficacy and safety?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

2 experts are featured in this video

Hepatitis B Epidemiology: Closing the Screening and Diagnosis Gap

ByRaymond Chung, MD,Douglas Dieterich, MD

August 13th 2026

Experts featured in this series.

Tafasitamab Plus R² in the Community: Familiarity, Adoption, and the Shift Toward Personalized Second-Line Care

ByRyan Haumschild, PharmD, MS, MBA, CPEL,Christina Poh, MD,Tara Graff DO, MS

August 13th 2026

Class Switching Outcomes in RA: Key Findings From the SELECT-SWITCH Trial

ByJulia Buchfuhrer, DO

August 13th 2026

2 experts are featured in this video

Understanding the Immune Pathophysiology Driving Chronic Hepatitis B

ByRaymond Chung, MD,Douglas Dieterich, MD

August 13th 2026

Comparing JAK Inhibitor Mechanisms of Action in RA Treatment

ByJulia Buchfuhrer, DO

August 13th 2026

Trending on AJMC

CMS Final Rule Ends Federal Medicaid, CHIP Funding for Youth Gender-Affirming Care

Trump Childhood Vaccine Order: What It Means for Parents and Payers

CAR T, Bispecifics Reshape Relapsed Lymphoma Care: Madhav Seshadri, MD

OCTOPUS Trial Aims to Speed Access to Rare Sarcoma Drugs

Employers With Claims Data Access Take More Cost Action, Survey Finds